29 completed, 5 terminated, 1 withdrawn. 21 Phase 1, 13 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 21 | Completed 17, Terminated 3, Withdrawn 1 |
| Phase 2 | 13 | Completed 11, Terminated 2 |
| Phase 3 | 1 | Completed 1 |
Follow ridaforolimus: new trials by email Literature Review of ridaforolimus trials Research Report on ridaforolimus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064) Ridaforolimus, Dalotuzumab, Exemestane - Breast Neoplasms | Phase 2 | Completed | Merck Sharp & Dohme LLC | 80 | 2012-07-04 | 2019-03-25 |
| Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1) dalotuzumab, ridaforolimus - Solid Tumors | Phase 1 | Completed | Merck Sharp & Dohme LLC | 21 | 2012-02-01 | 2016-06-17 |
| A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056) Ridaforolimus - Solid Tumors | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 20 | 2012-01-30 | 2019-03-01 |
| Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059) ridaforolimus - Cancer, Advanced | Phase 1 | Completed | Merck Sharp & Dohme LLC | 15 | 2011-07-05 | 2019-04-19 |
| Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids Ridaforolimus, Paclitaxel, carboplatin - Endometrial Cancer, Ovarian Cancer | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 24 | 2011-06-13 | 2017-08-30 |
| Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Soft Tissue Sarcoma ridaforolimus - Soft Tissue Sarcoma | Phase 1 | Withdrawn | The University of Texas Health Science Center at San Antonio | 2011-02-01 | 2012-07-12 | |
| Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049) ridaforolimus, MK-0752, MK-2206 - Advanced Cancer | Phase 1 | Completed | Merck Sharp & Dohme LLC | 65 | 2011-02-01 | 2015-08-27 |
| A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027) dalotuzumab, MK-0752, ridaforolimus - Neoplasms Malignant | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 47 | 2010-11-22 | 2018-08-16 |
| Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma ridaforolimus, vorinostat, biopsy - Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | Fox Chase Cancer Center | 16 | 2010-10-01 | 2021-02-21 |
| A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) ridaforolimus + dalotuzumab, exemestane, ridaforolimus - Breast Cancer | Phase 2 | Completed | Merck Sharp & Dohme LLC | 115 | 2010-09-17 | 2017-05-31 |
| The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050) Ridaforolimus + Dalotuzumab, Ridaforolimus, Dalotuzumab - Breast Cancer | Phase 1 | Completed | Merck Sharp & Dohme LLC | 63 | 2010-09-01 | 2015-01-21 |
| Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer Ridaforolimus - Non-Small Cell Lung Cancer | Phase 1 | Terminated | Angela Taber MD | 12 | 2010-09-01 | 2021-02-16 |
| Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044) Midazolam, Ridaforolimus - Relapsed or Refractory Advanced Cancer | Phase 1 | Completed | Merck Sharp & Dohme LLC | 16 | 2010-03-01 | 2015-04-10 |
| Ridaforolimus in Patients With Hepatic Insufficiency (MK-8669-046) ridaforolimus - Healthy Volunteers, Hepatic Insufficiency | Phase 1 | Completed | Merck Sharp & Dohme LLC | 19 | 2010-01-01 | 2015-04-29 |
| Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1) Ridaforolimus - Sarcoma | Phase 2 | Completed | Merck Sharp & Dohme LLC | 50 | 2009-11-01 | 2015-04-30 |
| A Study to Evaluate the Effect of MK-8669 (Ridaforolimus) on QTc Interval in Participants With Advanced Cancer (MK-8669-037) Ridaforolimus 100 mg, Ridaforolimus 40 mg, Placebo - Metastatic or Locally Advanced Cancer | Phase 1 | Completed | Merck Sharp & Dohme LLC | 23 | 2009-04-28 | 2019-05-06 |
| A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1) Lead-In Ridaforolimus, Comparator: Blinded Ridaforolimus, Comparator: Blinded Placebo - Non-Small Cell Lung Cancer | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 80 | 2009-03-01 | 2015-01-21 |
| Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038) Ridaforolimus Tablet, Ridaforolimus Intravenous (IV) Infusion - Advanced Cancers | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 7 | 2009-02-01 | 2019-02-18 |
| Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer ridaforolimus, gene expression analysis, immunohistochemistry staining method - Endometrial Cancer | Phase 2 | Completed | NCIC Clinical Trials Group | 35 | 2008-11-13 | 2023-08-04 |
| Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED) ridaforolimus, bevacizumab - Solid Tumor | Phase 1 | Completed | Merck Sharp & Dohme LLC | 17 | 2008-10-01 | 2015-02-13 |
Showing 20 of 35. Sign in to see all of them.
Neoplasms (9) · Breast Neoplasms (5) · Lymphoma (5) · Neoplasm Metastasis (5) · Recurrence (5) · Sarcoma (5) · Endometrial Neoplasms (4) · Ovarian Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Glioblastoma (2) · Multiple Myeloma (2) · Prostatic Neoplasms (2) · Bone Neoplasms (1) · Central Nervous System Neoplasms (1) · Colorectal Neoplasms (1)
Merck Sharp & Dohme LLC (30) · Angela Taber MD (1) · Fox Chase Cancer Center (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · NCIC Clinical Trials Group (1) · The University of Texas Health Science Center at San Antonio (1)
United States (8) · Canada (1)
Frank Haluska, M.D., Ph.D. (3) · Frank Haluska, M.D. (2) · Amit M. Oza, MD (1) · Angela Plette, MD (1) · Christopher Turner, MD (1) · Elizabeth Plimack (1) · Frank Haluska, MD, PhD (1) · Lisa Gore, MD (1) · Monica Mita, MD (1) · Robert Wenham, M.D. (1)
PMID 22067397, PMID 18202410, PMID 18451242, PMID 22037923, PMID 22143378, PMID 22695254, PMID 22878520, PMID 23211938, PMID 23403817, PMID 23615181, PMID 23659969, PMID 23715582, PMID 23829943, PMID 23921574, PMID 24827931, PMID 25173583, PMID 25239224, PMID 25290091, PMID 26091915, PMID 27185573, PMID 27713169, PMID 28324268, PMID 28595616, PMID 28681171
2004 (1)